Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial.~* Subjects from whom the Investigator believes a reasonable potential benefit from the long-term administration of brivaracetam may be expected.~Exclusion Criteria:~• Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (Type: EXPERIMENTAL): Brivaracetam at flexible dosing up to 200mg /day

Based on this trial design, predict the completion outcome and termination type (if applicable).